Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment
- 8 February 2012
- journal article
- Published by Springer Science and Business Media LLC in Cancer Microenvironment
- Vol. 5 (1), 83-93
- https://doi.org/10.1007/s12307-012-0098-7
Abstract
Hyperactive inflammatory responses following cancer initiation have led to cancer being described as a ‘wound that never heals’. These inflammatory responses elicit signals via NFκB leading to IL-6 production, and IL-6 in turn has been shown to induce epithelial to mesenchymal transition in breast cancer cells in vitro, implicating a role for this cytokine in cancer cell invasion. We previously have shown that conditioned medium derived from cancer-associated fibroblasts induced an Epithelial to Mesenchymal transition (EMT) in PMC42-LA breast cancer cells and we have now identify IL-6 as present in this medium. We further show that IL-6 is expressed approximately 100 fold higher in a cancer-associated fibroblast line compared to normal fibroblasts. Comparison of mouse-specific (stroma) and human-specific (tumor) IL-6 mRNA expression from MCF-7, MDA MB 468 and MDA MB 231 xenografts also indicated the stroma rather than tumor as a significantly higher source of IL-6 expression. Mast cells (MCs) feature in inflammatory cancer-associated stroma, and activated MCs secrete IL-6. We observed a higher MC index (average number of mast cells per xenograft section/average tumor size) in MDA MB 468 compared to MDA MB 231 xenografts, where all MC were observed to be active (degranulating). This higher MC index correlated with greater mouse-specific IL-6 expression in the MDA MB 468 xenografts, implicating MC as an important source of stromal IL-6. Furthermore, immunohistochemistry on these xenografts for pSTAT3, which lies downstream of the IL-6 receptor indicated frequent correlations between pSTAT3 and mast cell positive cells. Analysis of publically available databases for IL-6 expression in patient tissue revealed higher IL-6 in laser capture microdissected stroma compared to adjacent tissue epithelium from patients with inflammatory breast cancer (IBC) and invasive non-inflammatory breast cancer (non-IBC) and we show that IL-6 expression was significantly higher in Basal versus Luminal molecular/phenotypic groupings of breast cancer cell lines. Finally, we discuss how afferent and efferent IL-6 pathways may participate in a positive feedback cycle to dictate tumor progression.Keywords
This publication has 58 references indexed in Scilit:
- CPEB Control of NF-κB Nuclear Localization and Interleukin-6 Production Mediates Cellular SenescenceMolecular and Cellular Biology, 2011
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerBritish Journal of Cancer, 2010
- Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF ExpressionCell, 2010
- A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple MyelomaClinical Cancer Research, 2009
- Inflammation and EMT: an alliance towards organ fibrosis and cancer progressionEMBO Molecular Medicine, 2009
- Inflammation and cancer: how friendly is the relationship for cancer patients?Current Opinion in Pharmacology, 2009
- Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practiceRheumatology International, 2009
- Cancer-related inflammationNature, 2008
- A stromal gene signature associated with inflammatory breast cancerInternational Journal of Cancer, 2007